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Abstract: Seafood consumption enhances intake of omega-3 long-chain (≥C20) 
polyunsaturated fatty acids (termed LC omega-3 oils). Humans biosynthesize only small 
amounts of LC-omega-3, so they are considered semi-essential nutrients in our diet. Concern 
has been raised that farmed fish now contain lower LC omega-3 content than  
wild-harvested seafood due to the use of oil blending in diets fed to farmed fish. However, 
we observed that two major Australian farmed finfish species, Atlantic salmon  
(Salmo salar) and barramundi (Lates calcifer), have higher oil and LC omega-3 content 
than the same or other species from the wild, and remain an excellent means to achieve 
substantial intake of LC omega-3 oils. Notwithstanding, LC omega-3 oil content has 
decreased in these two farmed species, due largely to replacing dietary fish oil with poultry 
oil. For Atlantic salmon, LC omega-3 content decreased ~30%–50% between 2002 and 
2013, and the omega-3/omega-6 ratio also decreased (>5:1 to <1:1). Australian consumers 
increasingly seek their LC omega-3 from supplements, therefore a range of supplement 
products were compared. The development and future application of oilseeds containing 
LC omega-3 oils and their incorporation in aquafeeds would allow these health-benefitting 
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oils to be maximized in farmed Australian seafood. Such advances can assist with 
preventative health care, fisheries management, aquaculture nutrition, an innovative 
feed/food industry and ultimately towards improved consumer health. 
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1. Introduction 
The health benefits of omega-3 long-chain (≥C20) polyunsaturated fatty acids (LC-PUFA, also 
termed LC omega-3 oils) were first documented over three decades ago. Scientists observed that 
Greenland Eskimos had lower incidence of heart disease than other ethnic groups despite their high fat 
diet that was rich in the blubber of marine mammals [1]. The main LC omega-3 oils that have been 
attributed to this health benefit are eicosapentaenoic acid (EPA, 20:5ω3) and docosahexaenoic acid 
(DHA, 22:6ω3). For brevity, we use the term LC omega-3 here in consideration of both fatty acids, 
and also that of docosapentaenoic acid (DPA, 22:5ω3). Seafood has traditionally been the major source 
of these health-benefitting LC omega-3 oils [2]. Over the past decade the supply of farmed seafood has 
steadily increased, with the contribution of aquaculture to human food supplies now similar in volume 
to that of the wild catch harvest. 
Aquaculture is currently the main user of industrially produced fish oils, with around 90% of global 
fish oil production used in aquafeeds [3]. Fish oils are used in feeds for most aquaculture species to 
satisfy both essential fatty acid and energetic demands [4]. However, as aquaculture has expanded, the 
ability of existing supplies, including the increasing cost, of the wild harvest fish oil resource to meet 
industry needs has been largely surpassed [5]. Non-marine sources of oil, including vegetable and 
animal-derived, are therefore now also included in aquafeeds as alternatives to fish oil. However, both 
alternatives to fish oil have a lower content of LC omega-3 oil, which has the flow on effect of causing 
a lower concentration of LC omega-3 in farmed seafood products compared to that observed  
previously [6]. Generally Australian consumers and also, to our knowledge, consumers in most other 
countries are not fully aware of the lower LC omega-3 content now occurring in many farmed fish 
species. In addition to the trend of fish oil replacement largely by oil blends, other potential strategies 
exist, including finishing diets used prior to harvest and novel ingredients such as LC omega-3 
precursors [7]. However, to ensure the long-term supply of LC omega-3 oils for aquaculture there is a 
clear need for new and sustainable sources of these oils from fishery independent sources. 
Obtaining information on the composition of farmed seafood products is important for future 
developments within the aquaculture and associated feed manufacturing industries. This study was initiated 
to examine the fatty acid content and composition of two major Australian farmed fish species—
Atlantic salmon (Salmo salar) and barramundi (Lates calcifer). Particular emphasis was given to the LC 
omega-3 oils, and also the comparison of the changes seen in the fatty acid profiles between samples 
collected over 2010–2013 and earlier data for these same species obtained during 2002 when a largely 
fish oil diet was in use. As many Australian consumers increasingly seek their LC omega-3 from 
supplements, a range of supplement products also were examined and compared. 
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2. Experimental Section 
2.1. Sample Collection 
Norwegian quality cut (NQC) samples from three fresh fillets of farmed Atlantic salmon were 
obtained twice per year between December 2010 and November 2013. At CSIRO, the skin was removed 
and each sample was independently blended for two minutes in an OSKAR 400 continuous flow 
homogenizer. Whole barramundi were supplied to CSIRO in November 2010 by Marine Produce 
Australia Pty Ltd. (Broome, WA, Australia). The right fillet of each of three fish was used and the 
NQC analogous cut from that fillet of the barramundi was taken. The NQC sample was then minced, 
with a sample analysed for moisture content by gravimetric analysis after oven drying at 105 °C for  
24 h. The remainder of the sample was frozen, freeze dried, ground in a coffee grinder, and then 
shipped to Hobart for lipid extraction and analysis. 
Fourteen commercially produced omega-3 fish oil capsules were purchased from a local Hobart 
pharmacy. Each product was given a laboratory code: FO1-14. Oil capsules were cut open with a 
scalpel and the oil transferred to a glass vial using a glass pipette. 
2.2. Lipid Extraction 
NQC samples (typically between 1 and 3 g wet weight for Atlantic salmon, dry weight for 
barramundi) were quantitatively extracted overnight using a modified Bligh and Dyer [8] single-phase 
methanol-chloroform-water extraction (2:1:0.8 v/v/v). The phases were separated by addition of 
chloroform-water (final solvent ratio, 1:1:0.9 v/v/v methanol-chloroform-water). The total solvent 
extract (TSE) was concentrated using rotary evaporation at 40 °C, and total lipid content was 
determined gravimetrically. 
2.3. Fatty Acid Analysis 
An aliquot of the TSE of the farmed fish samples or the fish oils dissolved in chloroform was  
trans-methylated to produce FA methyl esters (FAME) using methanol–chloroform–conc. 
hydrochloric acid (3 mL, 10:1:1, 80 °C, 2 h) [9]. FAME were extracted into hexane–chloroform (4:1, 
1.8 mL). The samples were dried on a heat block (40 °C) under a stream of nitrogen gas, and an 
internal injection standard (C19 or C23 FAME) added. 
Samples were analysed by gas chromatography (GC) using an Agilent Technologies 7890A GC 
(Palo Alto, CA, USA) fitted with a Supelco Equity™-1 fused silica capillary column (15 m × 0.1 mm 
ID, 0.1 μm film thickness (Bellefont, PA, USA) an FID, a split/splitless injector and an Agilent 
Technologies 7683B Series auto sampler and injector. Helium was the carrier gas. Samples were 
injected in splitless mode at an oven temperature of 120 °C. After injection, the oven temperature was 
raised to 250 °C at 10 °C min
−1
 and finally to 270 °C at 3 °C min
−1
. Peaks were quantified with Agilent 
Technologies ChemStation software (Palo Alto, CA, USA). GC-mass spectrometric (GC-MS) analyses 
of selected samples were performed on a Finnigan Thermoquest GCQ GC-MS fitted with an  
on-column injector using Thermoquest Xcalibur software (Austin, TX, USA). The GC was fitted with a 
capillary column of similar polarity to that described above. Individual components were identified 
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using mass spectral data and by comparing retention time data with those obtained for authentic and 
laboratory standards. 
3. Results 
3.1. Oil Content 
Lipid content of the farmed barramundi samples averaged 10% (WW) in 2002 and 8.5% in 2010 
(wet weight, WW). Oil content of the farmed Atlantic salmon samples ranged from 6.7% to  
14.7% (WW). The 2010 and 2011 autumn Atlantic salmon samples contained lower oil content than all 
other samples collected from 2010 to 2013. 
3.2. Fatty Acid Composition and Content 
3.2.1. Farmed Fish 
Major fatty acids (FA) (as % of the total fatty acids, TFA) in farmed Australian Atlantic salmon 
harvested in 2002 were in decreasing order of abundance: 16:0 (18%), DHA (17%), 18:1ω9 (oleic 
acid, OLA; 15%), EPA (10%) and 16:1ω7 (6%) (Table 1). The three LC omega-3 PUFA—EPA + 
DPA + DHA accounted for 30% of the TFA. 
For farmed Atlantic salmon obtained in 2010–2013, the FA profile differed both from the  
2002 sample, and also over the 4 year period. Major FA in the 2010–2013 samples in decreasing order 
of abundance were: OLA, 16:0, 18:2ω6 (linoleic acid, LOA) and 16:1ω7 (Table 1); these four FA 
accounted for 57% (autumn 2010) rising to 72% of TFA in late spring 2013. In 2002, these four FA 
had accounted for 42% of TFA in farmed salmon. The next most abundant FA in the 2010–2013 
Atlantic salmon samples were: EPA, DHA and 18:0, with all three FA decreasing over this period. 
LOA increased from around 2.5-fold (autumn 2010) to 4-fold (spring 2013) compared to the 2002 
sampling, and the relative proportion of arachidonic acid (ARA) decreased over the 2010–2013 period. 
Expressed on an absolute basis (mg/100 g serve, WW), LC omega-3 content in farmed Atlantic 
salmon was 2010 mg/100 g in 2002, then ranged from as high as 1770 mg/100 g (spring 2010) 
decreasing to 980 mg/100 g in spring 2013 (Figure 1). The ratio of omega-3 PUFA/omega-6 PUFA 
was 7.8 in 2002 samples, and through 2010 to 2013 showed a steady decrease from 2.6 (autumn 2010) 
to 0.8 (spring 2013) (Figure 2). 
The FA profiles of farmed and wild caught barramundi are shown in Table 2. Major FA (as % TFA) 
in farmed samples from 2010 in decreasing order of abundance were: OLA, 16:0, LOA and 16:1ω7; 
these four FA accounted for approximately 60% of TFA in farmed barramundi. The next most 
abundant FA in farmed barramundi in 2010 were: EPA, DHA and 18:0. The relative level values for 
DHA in particular are lower than recorded for the 2002 farmed samples. 
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Table 1. Composition of fatty acids (as percent of total FA) in farmed Atlantic salmon  
(n = 3)—2002 and 2010–2013. 
Fatty acid 
Sample Date 
2002 2010 2010 2011 2011 2012 2012 2013 2013 
Winter Autumn Spring Autumn Summer Autumn Spring Autumn Spring 
14:0 5.5 2.1 2.7 2.8 2.5 2.4 1.8 1.9 1.7 
15:0 0.5 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.2 
16:4 0.3 0.7 0.6 0.5 0.5 0.3 0.2 0.3 0.2 
16:3 0.4 0.8 0.6 0.6 0.5 0.4 0.2 0.4 0.3 
16:1ω7c 6.2 8.3 7.0 7.4 7.2 6.4 6.8 6.9 4.9 
16:0 18.0 14.4 15.1 13.9 15.7 15.4 15.5 14.7 13.0 
17:1ω8c + a17:0 0.4 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.3 
17:0 0.5 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 
18:3ω6 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
18:4ω3 3.0 1.4 1.3 1.0 1.0 0.9 0.7 0.8 0.7 
18:2ω6 2.8 7.2 8.2 8.4 10.0 12.8 9.6 9.8 12.4 
18:3ω3 0.0 0.9 1.1 1.1 1.0 0.7 1.1 0.9 2.1 
18:1ω9c 14.5 27.0 29.2 33.8 33.8 33.0 39.0 38.8 42.7 
18:1ω7c 3.3 4.0 3.9 4.0 3.5 3.1 3.5 3.4 3.4 
18:1ω5c 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.1 
18:0 4.2 3.9 4.4 4.2 4.1 4.5 4.5 4.5 4.0 
20:4ω6 0.8 0.8 0.7 0.6 0.5 0.3 0.4 0.5 0.4 
20:5ω3 9.6 8.5 7.4 5.9 4.9 4.4 3.1 3.4 2.7 
20:3ω6 0.2 0.4 0.3 0.3 0.4 0.4 0.4 0.4 0.4 
20:4ω3 1.5 0.9 0.8 0.7 0.6 0.5 0.4 0.5 0.5 
C20PUFA 0.0 0.0 0.2 0.2 0.2 0.2 0.2 0.2 0.0 
20:2ω6 0.3 0.4 0.5 0.5 0.5 0.7 0.6 0.5 0.0 
20:1ω9c 1.7 1.4 1.4 1.7 1.5 1.8 1.8 1.7 1.7 
20:1ω7c 0.2 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.2 
20:0 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.2 
21:5ω3 0.6 0.4 0.4 0.3 0.3 0.3 0.2 0.2 0.1 
22:5ω6 0.3 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 
22:6ω3 17.0 7.8 6.7 5.0 5.1 5.4 4.8 4.9 4.0 
22:4ω6 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 
22:5ω3 3.8 3.8 2.8 2.5 2.2 1.9 1.4 1.6 1.2 
22:1ω11c 0.3 0.3 0.3 0.3 0.3 0.6 0.2 0.1 0.1 
22:1ω9c 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.2 
24:5ω3 0.0 0.2 0.2 0.0 0.2 0.1 0.1 0.1 0.0 
24:1ω11c 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 
24:1ω9c 0.5 0.2 0.2 0.0 0.2 0.2 0.2 0.1 0.2 
24:0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 
Other 2.7 2.0 1.8 1.5 1.4 1.4 1.4 1.5 1.4 
Sum 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Sum SFA 29.4 21.9 23.4 22.4 23.2 23.3 22.7 21.9 19.7 
Sum MUFA 29.2 43.1 44.1 49.6 48.2 46.8 53.3 52.8 54.7 
Sum Omega-3 PUFA 35.5 24.0 20.9 16.5 15.4 14.3 11.9 12.4 11.3 
Sum Omega-6 PUFA 4.6 9.3 10.0 10.4 11.8 14.6 11.6 11.8 13.6 
SFA, Saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. Prefix a denotes anteiso branching. 
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Figure 1. Content (±SD) of LC omega-3 oils (EPA + DPA + DHA, mg/100 g) in farmed 
Tasmanian Atlantic salmon sampled in 2002 [10] and 2010–2013. 
 
Figure 2. Ratio (±SD) of omega-3 PUFA/omega-6 PUFA in farmed Tasmanian Atlantic 
salmon, 2002 [10] and 2010–2013. 
 
Major fatty acids in wild caught barramundi were 16:0, OLA, 18:0, DHA and ARA (Table 2). Less 
abundant components included LOA, 16:1ω7c, EPA, 18:1ω7c and DPA. Freshwater samples had 
higher relative levels of LOA, OLA, 16:1ω7c, 18:1ω7c, 18:3ω3 (α-linolenic acid, ALA), 14:0 and 
lower EPA and DHA than the saltwater specimens. The greatest difference between the wild fresh and 
saltwater samples for any single FA was observed for DHA (5%, freshwater; 22%, saltwater). 
Saltwater fish contained higher levels of LC omega-3 oils than freshwater fish. In addition to 
containing considerably higher relative levels of DHA, the saltwater fish contained higher relative 
levels of total PUFA than freshwater fish (Table 2). The relative level of ω6 PUFA was similar in 
freshwater barramundi and saltwater fish. In freshwater fish ARA made up 7.1% of TFA, while in the 
saltwater wild fish it made up 12.2% of TFA. In contrast, in farmed barramundi collected in 2002 and 
Nutrients 2014, 6 1069 
 
 
2010, ARA levels were consistent at 0.6% to 0.7% and an order of magnitude lower. The ratio of ω3 
PUFA/ω6 PUFA differs between salt (1.9) and freshwater (0.8) barramundi (Table 2). 
Table 2. Composition of fatty acids (as percent of total FA) in wild and farmed barramundi. 
Fatty Acid 
1998 1998 2002 2010 
Freshwater Saltwater Farmed Farmed 
14:0 2.8 0.9 5.9 3.6 
15:0 0.9 0.6 0.6 0.3 
16:1ω7c 7.4 2.1 6.5 7.5 
16:0 27.8 22.4 19 17.7 
17:1ω8c + a17:0 0.9 0.7 0.5 0.3 
18:3ω6 0.4 0.3 0.3 0.3 
18:4ω3 0.4 0.6 1.9 1.3 
18:2ω6 4.8 1 5.5 9.8 
18:3ω3 1 0.2 0 1.1 
18:1ω9c 17.9 11.7 19.6 26.2 
18:1ω7c 4 2.1 2.9 3.2 
18:0 8.8 12.5 4.4 4.8 
20:4ω6 7.1 12.2 0.6 0.7 
20:5ω3 1.3 3.1 6.2 6.9 
20:3ω6 0.5 0.2 0.1 0.2 
20:4ω3 0.3 0 0.8 0.5 
20:2ω6 0.3 0.1 0.2 0.2 
20:1ω9c 0.6 0.3 3.5 1.1 
20:1ω7c 0.1 0 0.3 0.2 
20:0 0.3 0.2 0.2 0.3 
22:5ω6 0.4 0 0.3 0.2 
22:6ω3 6.1 21.6 10.2 5.4 
22:4ω6 1.2 1.2 0.1 0.1 
22:5ω3 1.6 2.2 2.5 2.1 
22:1ω11c 0 0 1.6 0.5 
22:1ω9c 0 0 0.5 0.1 
24:1ω9c 0.2 0.8 0.5 0.2 
Other 2.9 3 5.3 2.3 
Sum SFA 42.7 39.3 31.1 27.9 
Sum MUFA 31.7 17.7 37 40.7 
Sum Omega-3 PUFA 11.1 28.1 21.6 17.9 
Sum Omega-6 PUFA 14.5 14.9 7.2 10 
Omega-3/Omega-6 0.8 1.9 3 1.55 
2002 farmed barramundi [10]. 1998 and 2002 samples analysed using identical methods to 2010 fish. Wild 
caught barramundi data [11]. Abbreviations as used in Table 1. Prefix a denotes anteiso branching. 
Absolute concentration data (mg/100 g wet weight) for the LC omega-3 oils in wild harvest barramundi 
are shown in Figure 3. Wild saltwater fish contained higher DHA levels. For farmed barramundi, LC 
omega-3 content (EPA + DPA + DHA) was markedly higher than in the wild harvest samples, in 2002, 
although the content decreased to 790 mg/100 g in 2010 (Figure 3). 
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Figure 3. Content (±SD) (mg/100 g) of LC omega-3 oils (EPA + DPA + DHA) in wild 
caught (1998) [11] and farmed barramundi (2002 [10], 2010). 
 
3.2.2. Fish Oil Capsules 
The capsule samples were divided into three groups of LC omega-3 containing products. The first 
group was those products containing elevated EPA + DHA (FO1-5, Table 3); these products contained 
≥500 mg of EPA + DHA per capsule, which represents use of enrichment processes to obtain the 
product. One product reached this grouping largely based on its larger capsule size (Cenovis Fish Oil 
Plus, FO4, 1500 mg) compared with all other products. The second group of capsules (FO6-9) was the 
brands containing 180 mg EPA and 120 mg DHA per 1000 mg capsule. The Cenovis Fish Oil Plus 
(FO4) 1500 mg capsule product, when normalized to 1000 mg, contained the same DHA content as the 
other group 2 oils purchased, with EPA higher than for the other group 2 products. The third group 
(FO10-14) contained lower EPA + DHA content than group 1 and 2 oils, ranging from 52 to 160 mg  
per capsule. 
The FA profiles of the fish oil capsule products are shown in Table 4. All fish oil capsule 
supplements examined generally contained EPA + DHA at levels indicated on the product labels. The 
five group 1 fish oils contained 41%–78% EPA+DHA. The four group 2 oils—containing 180 mg 
EPA + 120 mg DHA—were very similar in composition containing around 30% EPA + DHA. The 
group 3 oils contained 16%–25% EPA + DHA. 
Other major FA present in group 2 and 3 oils included the saturated FA (SFA)—16:0, 18:0 and 
20:0, the monounsaturated FA (MUFA)—OLA, 18:1ω7c and 16:1ω7c. Several group 3 oils—wild 
salmon oil and cod-liver oil—both contained elevated levels (~18%) of LC-MUFA—20:1ω11c 
(salmon oil), 20:1ω9 (cod liver oil) and 22:1ω11c (Table 4)—distinguishing these two oils readily 
from other group 2 and 3 oils. The group 1 PUFA-enriched oils varied in composition. The Omega 
Brain oil (FO2) was elevated in DHA, with the other four group 1 products (FO1, FO3, FO4, FO5) 
each containing EPA > DHA. Products FO3 (Healthy Care Fish Oil One a Day) and FO5 (Natures 
Own Omega-3 Ultra) showed similar profiles, with 32%–36% EPA and 23% DHA. The omega-3 joint 
product (FO1) contained the highest EPA+DHA levels (78%), with a number of other PUFA present 
(18%); this oil contained the highest EPA/DHA ratio (3.4), and represents a highly purified  
PUFA-containing oil product compared with all other products. 
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Table 3. Fish oil capsules—brand and composition details as supplied by manufacturers. 
Brand Description Lab Code 
Capsule Size  
(mg)  
Number of  
Capsules 
Cost  
($) 
Cost ($) per  
Capsule 
EPA  
mg per  
Capsule 
DHA  
mg per  
Capsule 
EPA + DHA  
mg per  
Capsule 
Number of  
Caps for 500 mg  
EPA + DHA 
Group 1 
          
Blackmores Omega Joint FO1 1000 60 22.39 0.37 550 120 670 1 
Blackmores Omega Brain FO2 1000 60 22.39 0.37 100 500 600 1 
Healthy Care Fish oil One a Day FO3 1000 50 14.99 0.30 360 240 600 1 
Cenovis Fish oil Plus FO4 1500 62 16.69 0.27 335 185 520 2 
Natures Own Omega-3 Ultra FO5 1000 60 22.69 0.38 302 201 503 1 
Group 2 
          
Cenovis Fish oil with Omega-3 FO6 1000 180 13.69 0.08 180 120 300 2 
Blackmores Odorless Fish Oil + Vitamin D3 FO7 1000 100 12.99 0.13 180 120 300 2 
Healthy Care Fish oil FO8 1000 400 12.99 0.03 180 120 300 2 
Swisse Odorless Fish Oil  FO9 1000 200 22.99 0.11 180 120 300 2 
Group 3 
          
Swisse Wild salmon oil FO10 1000 200 22.99 0.11 80 80 160 4 
Blackmores Pregnancy FO11 1000 120 33.99 0.28 25 125 150 4 
Natures Own Fish oil + Glucosamine FO12 1100 90 20.99 0.23 90 60 150 4 
Swisse Wild krill oil (NKO) FO13 333 50 43.99 0.88 50 30 80 7 
Cenovis Cod liver oil * FO14 275 90 3.99 0.04 23 29 52 10 
* EPA + DHA data not supplied on label. Fatty acid data from [11]. 
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Table 4. Fatty acid composition (as % of total fatty acids) of fish oil capsule products. 
Sample Group 1 Group 2 Group 3 
 
FO1 FO2 FO3 FO4 FO5 FO6 FO7 FO8 FO9 FO10 FO11 FO12 FO13 FO14 
14:0 0.1 0.2 0.9 4.2 0.5 5.7 5.8 5.7 6.2 4.8 6.9 6.6 9.1 3.3 
15:0 0.0 0.1 0.0 0.3 0.0 0.5 0.4 0.5 0.5 0.4 0.7 0.4 0.4 0.3 
16:4 2.7 0.1 0.4 2.2 0.4 2.2 2.4 2.3 2.2 0.5 0.1 1.8 1.3 0.4 
16:3 1.8 0.1 0.4 1.6 0.2 1.5 1.8 1.5 1.6 0.5 0.1 1.4 0.3 0.3 
16:17c 0.5 0.8 1.7 6.9 1.4 9.6 9.4 9.6 9.7 6.8 3.8 8.0 6.8 6.6 
16:15c 0.0 0.0 0.0 0.1 0.0 0.2 0.2 0.2 0.2 0.4 0.1 0.2 0.5 0.3 
16:0 0.3 3.2 2.6 11.3 3.5 15.1 15.9 15.0 15.6 13.4 18.5 15.5 19.7 10.9 
i17:0 0.0 0.1 0.0 0.1 0.0 0.2 0.5 0.2 0.2 0.2 0.2 0.2 0.3 0.2 
17:18c + a17:0 0.0 0.2 0.1 0.2 0.1 0.4 0.4 0.4 0.4 0.5 0.6 0.3 0.4 0.7 
17:0 0.0 0.3 0.1 0.2 0.2 0.5 0.4 0.4 0.4 0.3 0.8 0.4 0.1 0.2 
18:36 0.6 0.1 0.1 0.2 0.1 0.3 0.2 0.3 0.2 0.0 0.1 0.2 0.2 0.1 
18:43 8.1 0.7 1.5 2.2 2.0 3.3 3.3 3.3 3.3 2.4 0.8 2.7 3.9 2.3 
18:26 0.2 1.1 0.9 2.5 1.6 1.4 1.1 1.6 1.4 2.5 8.3 7.8 2.1 2.2 
18:33 0.2 0.4 0.6 0.6 0.6 0.8 0.6 0.8 0.8 0.9 1.2 1.4 1.0 0.7 
18:19c 0.2 7.7 6.6 7.8 10.5 8.5 10.0 8.4 8.4 16.8 12.7 10.0 12.6 20.0 
18:17c 0.0 1.7 2.8 3.2 3.0 3.9 3.5 3.9 4.0 4.0 2.3 3.7 8.4 4.7 
18:15c 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.6 0.1 0.2 0.4 0.4 
18:0 0.1 3.9 2.8 2.7 3.5 3.4 3.2 3.4 3.5 2.4 7.8 5.3 1.4 2.6 
20:46 1.2 2.6 0.8 1.0 0.8 0.8 0.7 0.6 0.6 0.4 1.5 0.7 0.2 0.3 
20:53 EPA 60.4 14.5 35.6 27.4 31.8 18.9 20.0 19.0 18.7 9.1 5.4 15.1 16.9 8.8 
20:36 0.2 0.3 0.4 0.3 0.4 0.3 0.3 0.3 0.2 0.1 0.1 0.2 0.0 0.1 
20:43 0.9 0.9 1.8 1.2 1.5 1.0 0.9 1.0 1.0 1.2 0.4 0.8 0.4 0.8 
C20PUFA 0.1 0.1 0.8 0.4 0.4 0.3 0.3 0.3 0.3 0.1 0.0 0.3 0.0 0.1 
20:26 0.1 0.6 0.5 0.3 0.4 0.3 0.2 0.4 0.3 0.3 0.2 0.3 0.0 0.3 
20:111c 0.0 0.6 0.4 0.2 0.3 0.2 0.1 0.2 0.2 7.2 0.4 0.0 0.0 1.2 
20:19c 0.5 2.3 2.2 1.3 2.2 1.3 0.5 1.3 1.1 3.0 1.0 1.3 0.9 8.8 
20:17c 0.0 0.4 1.1 0.7 0.9 0.4 0.3 0.5 0.5 0.5 0.1 0.4 0.4 0.5 
20:0 0.0 0.7 0.6 0.3 0.5 0.3 0.2 0.3 0.3 0.3 0.4 0.4 0.1 0.1 
21:53 1.5 0.6 1.4 1.1 1.6 0.7 0.8 0.7 0.8 0.4 0.2 0.6 0.5 0.4 
22:56 0.0 1.1 0.5 0.4 0.4 0.3 0.3 0.3 0.3 0.1 1.3 0.3 0.0 0.1 
22:63 DHA 17.7 46.8 23.2 13.2 23.2 11.8 10.9 11.6 11.7 6.9 18.8 9.4 8.2 10.3 
22:46 0.1 0.5 0.3 0.2 0.2 0.2 0.1 0.2 0.2 0.0 0.3 0.1 0.0 0.1 
22:53 1.5 2.9 4.5 2.9 4.3 2.3 2.1 2.3 2.2 1.8 1.2 1.8 0.4 1.2 
22:111c 0.0 0.6 1.6 0.9 1.0 0.7 0.1 0.7 0.6 7.6 0.5 0.5 0.0 7.5 
22:19c 0.0 0.4 0.4 0.2 0.3 0.2 0.1 0.1 0.2 0.7 0.1 0.1 0.5 0.4 
22:0 0.0 0.4 0.2 0.2 0.2 0.1 0.3 0.1 0.1 0.1 0.2 0.2 0.0 0.1 
24:63 0.0 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
24:53 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.2 
24:19c 0.0 1.0 0.7 0.4 0.6 0.4 0.3 0.4 0.4 0.6 0.7 0.4 0.4 0.3 
24:0 0.0 0.3 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.4 0.1 0.0 0.0 
Sum other 1.0 1.2 0.9 1.0 1.0 1.8 2.3 1.7 1.7 2.0 1.5 0.9 1.6 2.2 
Sum 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
Sum EPA + DPA  
+ DHA 
79.7 64.3 63.2 43.5 59.4 33.0 33.0 32.9 32.6 17.8 25.4 26.3 25.5 20.2 
Omega-3/Omega-6 16.6 9.3 11.2 4.9 9.9 6.8 7.4 6.7 7.4 4.5 2.0 1.9 6.2 5.8 
Sample codes—refer to Table 3. Abbreviations as used in Table 1. Other FA (≤0.3% of total FA): 14:1ω5c, 4,8,12TMTD, i15:0, a15:0, 
i16:0, MBrFA:1, MBrFA, 17:1, C18PUFA, i18:0, 18:1ω7t, 18:1, 19:1, 20:1ω5c, 22:1ω7, 24:1ω11c. 
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4. Discussion 
4.1. Farmed Fish—Oil Content and Fatty Acid Profiles 
Total oil (lipid) content of farmed Atlantic salmon from 2010 to 2013 was generally similar to the 
oil content previously observed for Tasmanian Atlantic salmon [10]. Total lipid content in the whole 
body and fillet of most fish species, and barramundi are included in this regard, tends to increase with fish 
size [12]. In comparison, wild caught barramundi are considerably lower in lipid content (0.4% to 
0.9%, WW; shoulder portion) [11]. Farmed barramundi fed a fish oil-based diet and previously 
analysed contained various concentrations of lipid according to study, diet and fish size and fillet 
section analyzed; around 10% (WW) lipid [10], 1.3% to 30% lipid [13] and 8% to 14% lipid [14]. 
The relative level (as % TFA) values for EPA and in particular DHA for the two farmed fish species 
sampled in 2010–2013 are lower than those recorded in the 2002 analyses when both species were 
being fed a fish oil based-diet (barramundi—EPA 6.2%, DHA 10.2%; Tasmanian Atlantic salmon—EPA 
10%, DHA 17%) [10]. These 2010–2013 % composition values for EPA and DHA are also generally 
lower than those observed for most white muscle wild-caught fish species [11]. 
In addition to the reduction in EPA and DHA, the relative level of omega-6 PUFA was elevated in 
both farmed species sampled over the 2010–2013 period relative to 2002, due mainly to increased LOA. 
This leads to a dramatic shift in the ratio omega-3/omega-6 (i.e., from >7:1 in 2002, to ≤1:1 currently 
for Atlantic salmon). A recent study [15] followed the release of an American Heart Association 
advisory on omega-6 fatty acids and cardiovascular risk [16] and has indicated—―advice to 
specifically increase omega-6 intake is unlikely to provide the intended benefits, and may actually 
increase the risk of CHD and death‖. A further change in the FA profile of the two farmed fish is a 
large increase in the relative level of OLA. Collectively, this profile shift is reflecting a change in diet 
formulation to include higher proportions of terrestrial animal and plant-based oils, with concomitant 
reduction in fish oil. Similar changes in salmon oil quality occur in overseas markets [17]. Also 
notable over the 2002–2013 period was the overall decrease in SFA which are regarded as the ―least 
healthy‖ and are known precursors for endogenous cholesterol synthesis. Therefore at least one 
element of the current fish oil replacement strategy could be argued as improving the nutritional 
quality of farmed fish. It is the absolute content of the LC omega-3 that is the most critical issue in 
terms of the contribution that farmed fish make to the human diet. On an absolute (mg/100 g serve) 
basis, the LC omega-3 content values observed for farmed Atlantic salmon and barramundi sampled in 
2010–2013 are considerably higher than those found in most wild caught fish species [10,11], although 
the values from both species are lower than previously reported a decade ago in 2002 for these two 
farmed species fed a fish oil-based diet [10]. Large differences were observed between the autumn and 
spring/summer samples in 2010 and 2011. Tasmanian waters varied in water temperature through this 
period, together with the presence and degree of disease and other biological factors; these may be 
contributing factors to the observed differences. 
Wild harvest barramundi contained considerably lower absolute amounts of PUFA than the famed 
samples (Figure 3). However, a low oil content combined with similar high relative levels of omega-3 
in saltwater fish and both ω3 and ω6 PUFA in freshwater fish are nutritionally attractive features of the 
wild-harvest barramundi. The overall FA profile and lower LC omega-3 content of the wild specimens 
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provide no major nutritional advantage in terms of these key components. Both wild specimens had an 
omega-3/omega-6 ratio similar to or poorer that that found in farmed barramundi. 
Until about 10 years ago Australian and New Zealand fish farms were largely using feeds made 
with high inclusion of fishery products (fish meals and fish oils). Prior to this period, there was 
evidence that LC omega-3 content in farmed fish products remained high [2,3,10]. Increasing demand 
for fishery resources, such as fish oil, at a time where there is limited ability or capacity to increase 
sustainable harvest of wild fish stocks, has resulted in increased use of oils derived from  
non-traditional sources [7]. Oils now being routinely used include those from land plants (e.g., canola 
and palm oil) and rendered oils (e.g., poultry oil) [6]. The problem with the use of these oils is that 
they result in flesh with: (i) lower relative levels of LC omega-3 (as % of TFA); (ii) lower absolute 
content of the LC omega-3; and (iii) lower omega-3/omega-6 ratio. As the relative levels of these key 
LC omega-3 oils decrease, LOA and OLA increase. OLA and LOA are derived from the non-marine 
ingredients that are being increasingly substituted into aquafeeds, although most fish also have 
significant capacity to synthesis their own OLA from both lipid and non-lipid substrates [4]. 
Interest has existed in Australia and New Zealand on comparison of the LC omega-3 oil content of 
salmon farmed in the two locations. In Tasmania, the species farmed is Atlantic salmon (Salmo salar), 
whilst in New Zealand the predominant species is Chinook salmon (Oncorrhynchus tshawytscha, also 
termed king salmon). LC omega-3 content of the two species sampled at a similar time (spring 2012) 
showed Atlantic salmon containing 1117 ± 117 mg/100 g LC omega-3 with Chinook salmon at  
2568 ± 153 mg/100 g. The two species generally receive similar diets [18], and the differences in LC 
omega-3 content (and similarly for the SFA and omega-6 PUFA) result largely from the higher oil 
content of the fillet of farmed Chinook salmon (~25% oil content cf 10%–15% in Atlantic salmon). 
Atlantic salmon and barramundi have, when fed a FO-containing diet, provided an excellent source 
of beneficial omega-3 LC-PUFA for human consumption, but reduced concentrations of these 
nutrients, as occurs through the use of vegetable oil and/or animal fat diets, may reduce their 
nutritional benefit to consumers. Limited research has been performed to examine this issue. In one 
study [19], dietary intake of differently fed salmon (100% fish oil (FO), 50/50 FO/rapeseed oil,  
100% rapeseed oil) and the influence on markers of human atherosclerosis were compared. Significant 
differences between the human consumer groups were observed in the serum fatty acid profiles, 
especially for the levels of total omega-3 PUFA and the omega-3/omega-6 ratio, which were markedly 
increased in the FO-fed fish consuming group in contrast to the two other groups. In addition, 
significant reductions of serum TAG and of vascular cell adhesion molecule-1 and interleukin-6 were 
observed in patients receiving the FO-fed salmon diet when compared with the two other groups. The 
authors concluded that Atlantic salmon fed the FO-containing diet containing very high concentrations 
of omega-3 LC-PUFA seemed to produce favourable biochemical changes in patients with coronary 
heart disease risk factors when compared with ingestion of fillets with intermediate and low levels of 
the marine omega-3 LC-PUFA, where FO was replaced in part or in full by rapeseed oil [19]. To our 
knowledge, there have been no consumer trials with fish fed diets containing LOA, ALA and/or SDA 
rich oils versus FO derived EPA + DHA, and looking at the effects on consumers. 
Nutrients 2014, 6 1075 
 
 
A recent study tested whether Atlantic salmon smolt fed a diet with a higher DHA/EPA ratio and a 
lower content of LC omega-3 oils to that of conventional FO based diets would enhance deposition of 
LC omega-3 in the liver and muscle [20]. Comparisons were made between fish fed: (1) a FO diet;  
(2) a blend of 50% rapeseed and 50% tuna oil diet (termed model oil, MO1); (3) a blend of 50% 
rapeseed, 25% tuna and 25% FO diet (MO2); and (4) a blend of 50% FO and 50% poultry oil diet 
(FO/PO). The latter diet was representative of commercial diets in use in Australia at the time of the 
study, with the proportion of chicken fat increasing even further since the study was performed. The 
dietary DHA/EPA ratio was in the order MO1 > MO2 > FO/PO ~ FO. The LC omega-3 content was 
approximately 2-fold lower in the MO1, MO2 and FO/PO diets compared to the FO diet, with the 
relative levels (as % total FA) lowest in the MO1 diet. For the feeding trial, there were comparable 
contents of LC omega-3 in the muscle of the FO, MO 1 and FO/PO fed fish [20]. 
A major outcome for the feeding trial was the observation that a higher DHA/EPA ratio than that 
commonly occurring with FO-only diets used for Atlantic salmon was better suited for more efficient 
deposition of LC omega-3 in the flesh, in particular DHA. Evidence was therefore apparent for  
LC omega-3 ―sparing‖ in the Atlantic salmon smolt fed a diet with a high DHA/EPA ratio [20]. The 
use of a 50% FO and 50% PO blend in aquafeeds for Atlantic salmon, as was in the range 
commercially practiced in Australia in 2010, resulted in comparable LC omega-3 content in the  
muscle [20] and liver of juvenile Atlantic salmon to a FO fed fish. It is noteworthy that such an oil 
blend decreases the inefficient utilization of a 100% FO diet, due to the high loss of EPA in particular, 
and may be considered as an appropriate current strategy, in terms of LC omega-3 sparing, for present 
use in aquafeeds for Atlantic salmon [20]. The reduction of FO incorporation in the aquafeeds has also 
enhanced the sustainability of the industry, although sufficient FO still remains in the feeds used to 
ensure that farmed Tasmanian Atlantic salmon remains one of the best sources of the LC omega-3 oils 
available to Australian consumers. 
It is important to note that in spite of changes that have occurred in feeding practices, and the 
resulting lower content of LC omega-3 oils, the scope remains for the potential future use of new 
alternate sources of LC omega-3 to restore the content of these health-benefitting ingredients to those 
higher contents previously seen. 
Further research is needed to determine the optimum relative and absolute concentrations of dietary 
EPA and DHA to enhance their deposition in larger-sized commercially farmed Atlantic salmon. The 
rationale to pursue such studies is supported by recent developments in plant genomics. As this 
research field has progressed, important breakthrough steps have included: the isolation and 
characterization of genes from the marine microalgae encoding front-end desaturases involved in DHA 
biosynthesis, the isolation of highly efficient desaturases and elongases, the use of genes with omega-3 
substrate preference
 
and the development and use of a land plant (tobacco) leaf-based assay using 
interchangeable design principles to rapidly assemble multistep recombinant pathways
 
[21–23]. 
Progress with research on insertion of microalgal-derived genes leading to DHA production into a 
range of omega-3 C18 PUFA accumulating land plants has been reviewed [24–26]. 
Recent developments have resulted in oilseeds containing elevated LC omega-3 oils, including with 
fish oil-like proportions of DHA and an elevated omega-3/omega-6 ratio (2–5) [22,23,27]. These 
major breakthroughs can in the future provide the feed and aquaculture industries with an opportunity 
to both sustainably farm this key protein source for the growing global population, and enhance the 
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nutritional quality of farmed seafood products in terms of the health-benefitting LC omega-3 oils. 
Alternate feed-grade oils containing the desired FA profiles, in particular including a high DHA/EPA 
ratio, are not presently available. However, a realistic examination of the future steps required suggests 
that they can be a commercial reality by the end of this decade [22,23]. 
4.2. Fish Oil Capsules as Sources of EPA + DHA 
All products generally contained EPA + DHA at levels indicated on the product labels. The cost  
per 500 mg EPA + DHA (value generally advised for daily consumption by many nutritional and 
health groups [2]) varied markedly from $0.05 to $5.50 (Table 3), or from $20 to $2000 per annum 
(Figure 4). The lowest cost products, based on EPA + DHA levels alone, were those oils containing the 
conventional 180 mg EPA and 120 mg DHA per 1000 mg capsule (group 2). In the group 2 products, a 
four-fold cost difference occurred ($20–$79 pa, Table 3), although product specifications were 
identical. Consumers can have difficulties in compliance (e.g., consumption of multiple large 
capsules), and may prefer the range of enriched products (group 1) now available. The most expensive 
product based on EPA + DHA content was the krill oil, which was six-fold more expensive than the 
next most costly product. 
Figure 4. Cost per annum of fish oil products to supply 500 mg/day EPA + DHA. Sample 
codes refer to brands shown in Table 3. Enriched products—denotes group 1 brands 
containing concentrated EPA and/or DHA. 18/12 oils denotes—group 2 standard fish oils 
containing 180 mg/120 mg of EPA and DHA respectively. Other oils denotes—group 3 products 
containing varying proportions of EPA and DHA and may contain other components. 
 
5. Conclusions 
In summary, in comparison to 2002 samples of two major farmed Australian finfish species, 
Atlantic salmon and barramundi sampled in 2010–2013 have been shown to contain decreased relative 
levels and content of LC omega-3 oils (from 2014 mg/100 g in 2002 decreasing to 975 mg/100 g in 
spring 2013 for Atlantic salmon; 1970 mg/100 g in 2002 decreasing to 790 mg/100 g per serve for 
barramundi). These changes have resulted from the use of new, lower cost and sustainable ingredients 
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in farmed fish feed, necessitated by the inability of existing supplies together with the increasing cost 
of the wild harvest fish oil resource to meet the expanding needs of the aquaculture industry. 
Notwithstanding, these two widely available farmed fish species still remain an excellent source of the 
LC omega-3 oils, and in a broader context remain one of the best of all foods available for Australian 
consumers. All fish oil capsule supplements examined generally contained EPA + DHA at levels 
indicated on the product labels and, similar to the farmed seafood, such products can also represent a 
viable alternative source of LC omega-3 oils for consumers. 
Subject to consumer demand, one of the cost-effective strategies to increase the omega-3 content of 
the lipid profile of farmed fish could be to include enhanced levels of omega-3 rich vegetable oils, 
and/or finishing diets with higher inclusions of marine oils [6]; such a strategy may result in grades of 
farmed seafood product being available for purchase that contain higher content of LC omega-3 than 
standard products grown using a predominately non-marine oil based diet. In the longer term, other 
strategies to consider include: selection for enhanced delta-5 and delta-6 desaturase activities (the key 
enzymes converting shorter chain omega-3 to EPA and DHA) and the use of alternate long-chain 
omega-3 oil sources, including new oil seeds containing EPA and DHA. 
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